Ngā hua rapu

Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report mā Todaro, Juliana, Bollmann, Patrícia Weinschenker, Rother, Edna Terezinha, Giglio, Auro del

Whiwhi kuputuhi katoa

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia mā Piyanuch Kongtim, Uday Popat, Antonio Jiménez, Sameh Gaballa, Riad El Fakih, Gabriela Rondón, Julianne Chen, Carlos Bueso-Ramos, Gautam Borthakur, Naveen Pemmaraju, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Amin M. Alousi, Chitra Hosing, Paolo Anderlini, Issa F. Khouri, Partow Kebriaei, Börje S. Andersson, Betül Oran, Katayoun Rezvani, David Marín, Elizabeth J. Shpall, Richard E. Champlin, Stefan O. Ciurea

Whiwhi kuputuhi katoa

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial mā Charles Craddock, Nadira Jilani, Shamyla Siddique, Christina Yap, Josephine Khan, Sandeep Nagra, Janice Ward, Paul Ferguson, Peter Hazlewood, Richard J. Buka, Paresh Vyas, Oliver Goodyear, Eleni Tholouli, Charles Crawley, Nigel H. Russell, Jenny Byrne, Ram Malladi, John A. Snowden, Mike Dennis

Whiwhi kuputuhi katoa

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia mā Ashkan Emadi, Rawan Faramand, Brandon Carter‐Cooper, Seda S. Tolu, Laurie Ford, Rena G. Lapidus, Meir Wetzler, Eunice S. Wang, Arash Etemadi, Elizabeth A. Griffiths

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers mā Huili Li, Katherine B. Chiappinelli, Angela A. Guzzetta, Hariharan Easwaran, Ray-Whay Chiu Yen, Rajita Vatapalli, Michael J. Topper, Jianjun Luo, Roisín M. Connolly, Nilofer S. Azad, Vered Stearns, Drew M. Pardoll, Nancy E. Davidson, Peter A. Jones, Dennis J. Slamon, Stephen B. Baylin, Cynthia A. Zahnow, Nita Ahuja

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes mā Lewis R. Silverman, Pierre Fenaux, Ghulam J. Mufti, Valeria Santini, Eva Hellström‐Lindberg, Norbert Gattermann, Guillermo Sanz, Alan F. List, Steven D. Gore, John F. Seymour

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Hypomethylation and up-regulation of<i>PD-1</i>in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation mā Andreas Due Ørskov, Marianne Bach Treppendahl, Anni Skovbo, Mette Skov Holm, Lone S. Friis, Marianne Hokland, Kirsten Grønbæk

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Activity of azacitidine in chronic myelomonocytic leukemia mā Rubens Costa, Haifaa Abdulhaq, Bushra Haq, Richard K. Shadduck, Joan Latsko, Mazen S. Zenati, Folefac Atem, James M. Rossetti, Entezam Sahovic, John Lister

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry mā Teresa Bernal, Pablo Martínez‐Camblor, Joaquín Sánchez‐Garcia, R. de Paz, Elisa Luño, Benet Nomdedeu, M. Ardanaz, Carmen Pedro, Mari Luz Amigo, Blanca Xicoy, Consuelo del Cañizo, Mar Tormo, Jürgen Floege, David Valcárcel, Salut Brunet, Luis Benlloch, Guillermo Sanz

Whiwhi kuputuhi katoa

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid... mā Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jorge E. Cortés, Naveen Pemmaraju, Sherry R. Pierce, Kate J. Newberry, Naval Daver, Srđan Verstovšek

Whiwhi kuputuhi katoa

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts mā Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James D. Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal, Haifa Kathrin Al‐Ali, Giovanni Martinelli, José Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, S. Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies mā Eric Laille, Tao Shi, Guillermo Garcia‐Manero, Christopher R. Cogle, Steven D. Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J. MacBeth

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients mā Sylvain Thépot, Raphaël Itzykson, Valérie Seegers, Christian Récher, Emmanuel Raffoux, Bruno Quesnel, Jacques Delaunay, Thomas Cluzeau, Anne Marfaing Koka, Aspasia Stamatoullas, Marie‐Pierre Chaury, Caroline Dartigeas, Stéphane Chèze, Anne Banos, Pierre Morel, Isabelle Plantier, Anne‐Laure Taksin, Jean Pierre Marolleau, Cécile Pautas, Xavier Thomas, Françoise Isnard, Blandine Bève, Yasmine Chaït, Agnès Guerci, Norbert Vey, François Dreyfus, Lionel Adès, Norbert Ifrah, Hervé Dombret, Pierre Fenaux, Claude Gardin

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myel... mā Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans, Marinus van Marwijk Kooy, Ron Schaafsma, Bart J. Biemond, Aart Beeker, Mels Hoogendoorn, Bastiaan P. van Rees, Okke de Weerdt, Jurgen Wegman, Ward J. Libourel, Sylvia A. Luykx‐de Bakker, Monique C. Minnema, Rolf E. Brouwer, Fransien Croon‐de Boer, Matthijs Eefting, Kon‐Siong G. Jie, Arjan A. van de Loosdrecht, Jan Koedam, Nic J.G.M. Veeger, Edo Vellenga, Gerwin Huls

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome mā Iskra Pusic, Jaebok Choi, Mark A. Fiala, Feng Gao, Matthew Holt, Amanda F. Cashen, Ravi Vij, Camille N. Abboud, Keith Stockerl‐Goldstein, Meghan A. Jacoby, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio

Whiwhi kuputuhi katoa

Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome mā Marcos de Lima, Sergio Giralt, Peter F. Thall, Leandro de Pádua Silva, Roy B. Jones, Krishna V. Komanduri, Thomas M. Braun, Hoang Q. Nguyen, Richard E. Champlin, Guillermo Garcia‐Manero

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Guadecitabine (SGI‐110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin mā Yuting Kuang, Anthony B. El-Khoueiry, Pietro Taverna, Mats Ljungman, Nouri Neamati

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects mā Quteba Ebrahem, Reda Z. Mahfouz, Kwok Peng Ng, Yogen Saunthararajah

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine* mā Valeria Santini, Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg, Lewis R. Silverman, Alan F. List, Steven D. Gore, John F. Seymour, Jay T. Backstrom, Charles L. Beach

Whiwhi kuputuhi katoa

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study mā Eric A. Benson, Todd C. Skaar, Yunlong Liu, Kenneth P. Nephew, Daniela Matei

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa